From time to time we use our own capital to make strategic investments in companies that fall outside our managed funds’ scope of interest. These investments are targeted at situations where our team is well positioned to have an especially high impact – frequently because of our special expertise and almost always because of our network of relationships throughout the industry. When making these kinds of investments, we seek out opportunities where members of our team can be involved in the startup (or even pre-startup) phase of the portfolio company’s life.
January 5, 2017 – Amplyx Pharmaceuticals Appoints Ciara Kennedy, Ph.D., as President and Chief Executive Officer
November 16, 2016 – FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections
September 12, 2016 – Amplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections
February 9, 2016 – Amplyx Pharmaceuticals Expands Management Team and Increases Its Series B Financing to $49.2 Million